Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxocobalamin Injection in Pediatric Methylmalonic Acidemia (Phase III)
CTR20260188Phase 3Active
- Sponsor
- China Resources Double-Crane Pharmaceutical
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hydroxocobalamin in methylmalonic acidemia (MMA), hyperhomocysteinemia, sponsored by China Resources Double-Crane Pharmaceutical. Started Jan 2026; status: active.
02
Drugs
hydroxocobalamin
03
Conditions
methylmalonic acidemia (MMA)hyperhomocysteinemia
Beyond the preview
Go deeper on CTR20260188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260188.